We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Fed. Circ. Backs Decision Axing 4 Acorda MS Drug Patents

Law360 (September 10, 2018, 9:01 PM EDT) -- A split Federal Circuit panel on Monday upheld a judge’s decision that four patents on Acorda Therapeutics Inc.’s multiple sclerosis drug Ampyra are invalid as obvious, clearing the way for competing generic versions and putting the drug’s over $500 million in annual sales in jeopardy.

The appeals court held 2-1 that Chief Judge Leonard Stark of the District of Delaware was correct when he ruled last year that Acorda’s claimed method of improving the ability of multiple sclerosis patients to walk would be obvious to person...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.